Kevin Li joined Expansion Therapeutics in September of 2022 as Senior Director, Program Management.  He previously served as the Program Executive for the Epilepsy Franchise at Praxis Precision Medicines where he led a cross functional team that progressed a small molecule and an ASO through IND clearance, both programs currently being evaluated in patients with rare developmental and epileptic encephalopathies. Prior to his position with Praxis, Kevin held roles of increasing responsibility at bluebird bio, where he focused on developing gene therapy products for sickle cell disease and beta thalassemia as a Director, Portfolio and Program Management.  He also previously held roles in medical affairs and clinical operations functions at Sanofi Genzyme and Medtronic. 

He received his Master of Public Health concentrating in healthcare management from Yale University and his Bachelor of Arts and Sciences in Biology and Finance from Muhlenberg College.